Log In
BCIQ
Print this Print this
 

muparfostat (PI-88)

  Manage Alerts
Collapse Summary General Information
Company TBG Diagnostics Ltd.
DescriptionSulfated mannopentaose phosphate anti-angiogenic agent that inhibits VEGF, FGF and heparanase activity
Molecular Target Vascular endothelial growth factor (VEGF) ; Fibroblast growth factor (FGF)
Mechanism of ActionAngiogenesis inhibitor; Vascular endothelial growth factor (VEGF) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationLiver cancer
Indication DetailsAdjuvant treatment of hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection; Treat hepatocellular carcinoma (HCC) following primary tumor resection; Treat primary liver cancer
Regulatory Designation U.S. - Orphan Drug (Adjuvant treatment of hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection);
EU - Orphan Drug (Adjuvant treatment of hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection)
PartnerMedigen Biotechnology Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/17/2010

Undisclosed

0

Undisclosed

05/25/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today